| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2001; 40: 1135-1140
© 2001 British Society for Rheumatology
Original Papers |
Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis
Department of Dermatology, Kanazawa University School of Medicine, Kanazawa, Japan
Objective. To determine the clinical associations of the levels of anti-topoisomerase I (topo I) antibody in patients with systemic sclerosis (SSc).
Methods. Anti-topo I antibody levels were determined by enzyme-linked immunosorbent assay. In a longitudinal study, 125 sera from 21 patients were analysed during a follow-up period of 0.2–4.7 yr.
Results. Anti-topo I antibody levels were correlated positively with skin thickness score and renal vascular resistance, and inversely with percentage vital capacity. In the longitudinal study, five patients with a low anti-topo I antibody level at their first visit exhibited a stable antibody level or a small decrease in the level during the follow-up period, and their skin sclerosis was stable. Of 16 patients with a high anti-topo I antibody level at their first visit, seven showed a stable level, four had an increasing level and five had a decreasing level. The decreasing levels were accompanied mainly by atrophic skin change during the follow-up period, whereas the increasing levels were associated with new onset or worsening of organ involvement.
Conclusions. These results suggest the potential clinical significance of anti-topo I antibody levels in evaluating disease severity and the prognosis in SSc.
KEY WORDS: Systemic sclerosis, Anti-topoisomerase I antibody, Modified Rodnan total skin thickness score, Autoantibody level, Longitudinal study.
Correspondence to: S. Sato, Department of Dermatology, Kanazawa University School of Medicine, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U A Walker, A Tyndall, L Czirjak, C Denton, D Farge-Bancel, O Kowal-Bielecka, U Muller-Ladner, C Bocelli-Tyndall, M Matucci-Cerinic, and EUSTAR Co-authors Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database Ann Rheum Dis, June 1, 2007; 66(6): 754 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sato, M. Fujimoto, M. Hasegawa, K. Komura, K. Yanaba, I. Hayakawa, T. Matsushita, and K. Takehara Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis Rheumatology, October 1, 2004; 43(10): 1261 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Q. Hu, N. Fertig, T. A. Medsger Jr, and T. M. Wright Molecular Recognition Patterns of Serum Anti-DNA Topoisomerase I Antibody in Systemic Sclerosis J. Immunol., August 15, 2004; 173(4): 2834 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Asano, M. Fujimoto, N. Yazawa, S. Shirasawa, M. Hasegawa, H. Okochi, K. Tamaki, T. F. Tedder, and S. Sato B Lymphocyte Signaling Established by the CD19/CD22 Loop Regulates Autoimmunity in the Tight-Skin Mouse Am. J. Pathol., August 1, 2004; 165(2): 641 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cutolo, C. Pizzorni, M. Tuccio, A. Burroni, C. Craviotto, M. Basso, B. Seriolo, and A. Sulli Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis Rheumatology, June 1, 2004; 43(6): 719 - 726. [Abstract] [Full Text] [PDF]
|
|